|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GPR155 |
Gene summary for GPR155 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GPR155 | Gene ID | 151556 |
| Gene name | G protein-coupled receptor 155 | |
| Gene Alias | DEP.7 | |
| Cytomap | 2q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q7Z3F1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151556 | GPR155 | LZE4T | Human | Esophagus | ESCC | 6.54e-03 | 5.75e-02 | 0.0811 |
| 151556 | GPR155 | LZE24T | Human | Esophagus | ESCC | 8.40e-26 | 1.16e+00 | 0.0596 |
| 151556 | GPR155 | P2T-E | Human | Esophagus | ESCC | 2.60e-07 | 5.79e-02 | 0.1177 |
| 151556 | GPR155 | P4T-E | Human | Esophagus | ESCC | 1.91e-03 | 1.74e-01 | 0.1323 |
| 151556 | GPR155 | P9T-E | Human | Esophagus | ESCC | 2.04e-22 | 6.65e-01 | 0.1131 |
| 151556 | GPR155 | P10T-E | Human | Esophagus | ESCC | 3.99e-05 | 3.15e-02 | 0.116 |
| 151556 | GPR155 | P11T-E | Human | Esophagus | ESCC | 4.30e-10 | 6.74e-01 | 0.1426 |
| 151556 | GPR155 | P12T-E | Human | Esophagus | ESCC | 3.05e-05 | 1.51e-01 | 0.1122 |
| 151556 | GPR155 | P15T-E | Human | Esophagus | ESCC | 2.60e-03 | 6.09e-02 | 0.1149 |
| 151556 | GPR155 | P16T-E | Human | Esophagus | ESCC | 1.52e-04 | -2.74e-02 | 0.1153 |
| 151556 | GPR155 | P19T-E | Human | Esophagus | ESCC | 4.58e-07 | 7.39e-01 | 0.1662 |
| 151556 | GPR155 | P22T-E | Human | Esophagus | ESCC | 7.68e-07 | 4.57e-02 | 0.1236 |
| 151556 | GPR155 | P23T-E | Human | Esophagus | ESCC | 1.10e-05 | 3.27e-01 | 0.108 |
| 151556 | GPR155 | P26T-E | Human | Esophagus | ESCC | 1.37e-03 | 6.47e-02 | 0.1276 |
| 151556 | GPR155 | P27T-E | Human | Esophagus | ESCC | 3.81e-10 | 2.64e-01 | 0.1055 |
| 151556 | GPR155 | P28T-E | Human | Esophagus | ESCC | 1.13e-11 | 2.43e-01 | 0.1149 |
| 151556 | GPR155 | P30T-E | Human | Esophagus | ESCC | 3.61e-05 | 2.70e-01 | 0.137 |
| 151556 | GPR155 | P39T-E | Human | Esophagus | ESCC | 6.44e-06 | 8.63e-02 | 0.0894 |
| 151556 | GPR155 | P47T-E | Human | Esophagus | ESCC | 4.36e-04 | 8.96e-02 | 0.1067 |
| 151556 | GPR155 | P48T-E | Human | Esophagus | ESCC | 3.16e-03 | 2.55e-03 | 0.0959 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GPR155 | SNV | Missense_Mutation | c.740N>A | p.Gly247Glu | p.G247E | Q7Z3F1 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| GPR155 | SNV | Missense_Mutation | c.1663N>T | p.Asp555Tyr | p.D555Y | Q7Z3F1 | protein_coding | deleterious(0.01) | benign(0.251) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GPR155 | SNV | Missense_Mutation | c.2050N>C | p.Glu684Gln | p.E684Q | Q7Z3F1 | protein_coding | tolerated(0.42) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GPR155 | SNV | Missense_Mutation | c.1423N>C | p.Glu475Gln | p.E475Q | Q7Z3F1 | protein_coding | tolerated(0.14) | possibly_damaging(0.762) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GPR155 | SNV | Missense_Mutation | c.490N>C | p.Glu164Gln | p.E164Q | Q7Z3F1 | protein_coding | deleterious(0.03) | probably_damaging(0.957) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GPR155 | SNV | Missense_Mutation | c.862C>G | p.Leu288Val | p.L288V | Q7Z3F1 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GPR155 | insertion | Nonsense_Mutation | novel | c.2357_2358insCATATTCTAGCCGCGTATTCATTAGTTTTTAGCTG | p.Val787IlefsTer3 | p.V787Ifs*3 | Q7Z3F1 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| GPR155 | insertion | Frame_Shift_Ins | novel | c.2444_2445insATGGATGTGGAACCTGTGCATATGGAGGGTCAACTGTACTA | p.Gln816TrpfsTer90 | p.Q816Wfs*90 | Q7Z3F1 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GPR155 | insertion | Frame_Shift_Ins | novel | c.1298_1299insA | p.Asn433LysfsTer4 | p.N433Kfs*4 | Q7Z3F1 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GPR155 | insertion | Nonsense_Mutation | novel | c.1161_1162insGGTGGTATGCATCTGTAATCCCAGCTACCTGGGTGGCTGAGGCACAAGAGTC | p.Ile388GlyfsTer6 | p.I388Gfs*6 | Q7Z3F1 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |